Teva Pharmaceutical Industries (TEVA) Convertible Debt (2009 - 2010)
Teva Pharmaceutical Industries (TEVA) posted quarterly Convertible Debt of $13.0 million for Q4 2010, down 98.41% year-on-year from $817.0 million in Q4 2009, and down 7.14% on a QoQ basis from $14.0 million in Q3 2010.
Teva Pharmaceutical Industries (TEVA) Convertible Debt (2009 - 2010) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Convertible Debt for 2 consecutive years, with $13.0 million the latest figure, recorded in Q4 2010.
- Quarterly Convertible Debt fell 98.41% year-over-year to $13.0 million in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $13.0 million (down 98.41% YoY) and the FY2010 annual result came in at $13.0 million, down 98.41% from the prior year.
- Convertible Debt slipped to $13.0 million in Q4 2010 per TEVA's latest filing, from $14.0 million in the prior quarter.
- Over the last five years, Convertible Debt for TEVA reached as high as $1.2 billion in Q1 2009 and fell as low as $13.0 million in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2010 | 13.00 Mn |
| Sep 30, 2010 | 14.00 Mn |
| Jun 30, 2010 | 21.00 Mn |
| Mar 31, 2010 | 47.00 Mn |
| Dec 31, 2009 | 817.00 Mn |
| Sep 30, 2009 | 832.00 Mn |
| Jun 30, 2009 | 861.00 Mn |
| Mar 31, 2009 | 1.21 Bn |